Molecular characteristics of patients with colorectal signet-ring cell carcinoma with different ABO blood groups

Abstract

Colorectal signet-ring cell carcinoma (SRCC) is a rare subtype of malignant adenocarcinomas. Its biomarker and molecular characteristics remain controversial, and there are no specific therapeutic targets and strategies for clinical treatment. A retrospective study was performed and the extracted data included patients’ clinical variables and genomics (either 19-gene or 1021-gene panel NGS). From 2010 to 2021, 64 patients were included. The blood groups of 27 (42.2%), 18 (28.1%), 12 (18.8%), and 7 (10.9%) patients were O, A, B, and AB, respectively. We found that O was a unique blood group which had better prognosis different from non-O blood groups, characterized by a low frequency of KRAS mutations, a high frequency of heterozygous at each HLA class I locus and greater numbers of tumor mutational burden (TMB). Patients with blood group A with high frequency KRAS mutations and patients with blood group B with anemia and metabolic abnormalities had worse OS and needed targeted treatment. The study initially revealed genomic changes in SRCC patients with different blood groups and could advance the understanding and precision treatment of the colorectal SRCC. Blood group O might be a novel target for immunotherapy of colorectal SRCC.

The Association between ABO Blood Group and the Risk of Colorectal Cancer: A Systematic Literature Review and Meta-Analysis

“…After analyzing the others, it was revealed that the type A blood group frequency was high among CC patients, and the type AB blood group was fewer than the other types, which consisted of Zhang et al, (2014) study's results indicated that the type A blood group was higher than the other groups among CC patients. Also, in Zhang et al, (2022). Study, a retrospective study that was done on 64 pretreatments, and colorectal SRCC specimens, it was shown that the A-type blood group was predominant, and after that, the type B blood group in cancer, which was in coordination with our study.…”

“…The role of blood groups in developing cancers was revealed in an Arid study in 1953 that A blood group is related to gastric cancer. Nowadays, the effect of the A blood group on developing gastric, uterus, neurological malignancies, kidney cancers, B blood groups in the esophagus, and O blood groups in melanoma cancers is revealed (Gömeç and Özden, 2021;Kahramanca et al, 2018;Senger et al, 2021;Slater et al, 1993;Wei et al, 2019;Zhang et al, 2022). Many studies have been done to assess the effect of blood groups on developing diseases and, among them, cancers (Abegaz, 2021;Bahardoust et al, 2019;Yingying Mao et al, 2019;Song et al, 2019;Yu et al, 2020).…”